815 related articles for article (PubMed ID: 29187509)
21. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
22. Diabetes mellitus induced by PD-1 and PD-L1 inhibitors: description of pancreatic endocrine and exocrine phenotype.
Marchand L; Thivolet A; Dalle S; Chikh K; Reffet S; Vouillarmet J; Fabien N; Cugnet-Anceau C; Thivolet C
Acta Diabetol; 2019 Apr; 56(4):441-448. PubMed ID: 30284618
[TBL] [Abstract][Full Text] [Related]
23. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
24. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
[TBL] [Abstract][Full Text] [Related]
25. Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma.
Morganstein DL; Lai Z; Spain L; Diem S; Levine D; Mace C; Gore M; Larkin J
Clin Endocrinol (Oxf); 2017 Apr; 86(4):614-620. PubMed ID: 28028828
[TBL] [Abstract][Full Text] [Related]
26. Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor.
Escandon J; Peacock S; Trabolsi A; Thomas DB; Layka A; Lutzky J
J Immunother Cancer; 2017; 5():3. PubMed ID: 28105370
[TBL] [Abstract][Full Text] [Related]
27. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
[TBL] [Abstract][Full Text] [Related]
28. Management of toxicities of immune checkpoint inhibitors.
Spain L; Diem S; Larkin J
Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
[TBL] [Abstract][Full Text] [Related]
29. Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity.
Gutzmer R; Koop A; Meier F; Hassel JC; Terheyden P; Zimmer L; Heinzerling L; Ugurel S; Pföhler C; Gesierich A; Livingstone E; Satzger I; Kähler KC;
Eur J Cancer; 2017 Apr; 75():24-32. PubMed ID: 28214654
[TBL] [Abstract][Full Text] [Related]
30. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
[TBL] [Abstract][Full Text] [Related]
31. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
32. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
[TBL] [Abstract][Full Text] [Related]
33. Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin.
Jain V; Mohebtash M; Rodrigo ME; Ruiz G; Atkins MB; Barac A
J Immunother; 2018 Sep; 41(7):332-335. PubMed ID: 29965858
[TBL] [Abstract][Full Text] [Related]
34. Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma.
Ivashko IN; Kolesar JM
Am J Health Syst Pharm; 2016 Feb; 73(4):193-201. PubMed ID: 26843495
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint blocker-related sarcoid-like granulomatous inflammation: a rare adverse event detected in lymph node aspiration cytology of patients treated for advanced malignant melanoma.
Rodriguez EF; Lipson E; Suresh K; Cappelli LC; Monaco SE; Maleki Z
Hum Pathol; 2019 Sep; 91():69-76. PubMed ID: 31279873
[TBL] [Abstract][Full Text] [Related]
36. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
37. What do we know about cancer immunotherapy? Long-term survival and immune-related adverse events.
Miranda Poma J; Ostios Garcia L; Villamayor Sanchez J; D'errico G
Allergol Immunopathol (Madr); 2019; 47(3):303-308. PubMed ID: 29983240
[TBL] [Abstract][Full Text] [Related]
38. Cancer immunotherapy-associated hypophysitis.
Solinas C; Porcu M; De Silva P; Musi M; Aspeslagh S; Scartozzi M; Willard-Gallo K; Mariotti S; Saba L
Semin Oncol; 2018 Jun; 45(3):181-186. PubMed ID: 30352754
[TBL] [Abstract][Full Text] [Related]
39. [Immune-related adverse events by immune checkpoint inhibitors].
Kadono T
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):83-89. PubMed ID: 28603205
[TBL] [Abstract][Full Text] [Related]
40. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
